Savolitinib in <i>MET</i>-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature Medicine, Published online: 01 June 2026; doi:10.1038/s41591-026-04459-7

As presented at the 2026 ASCO Annual Meeting, in a phase 2 trial that included an exploratory and a pivotal phase, treatment of patients with MET-amplified gastric or gastroesophageal junction adenocarcinoma with the selective MET tyrosine kinase inhibitor savolitinib showed promising clinical efficacy.

Source: www.nature.com